This page shows the latest infliximab news and features for those working in and with pharma, biotech and healthcare.
These savings derived mainly from trastuzumab and bevacizumab to treat a range of cancers, infliximab for autoimmune diseases, and pegfilgrastim to treat chemotherapy-related neutropenia, says the report.
The expanded Solidarity PLUS trial will test artesunate, imatinib and infliximab on hospitalised COVID-19 patients in a trial that will involve thousands of researchers in 52 countries. ... The drugs – artesunate, imatinib and infliximab – were
Its biosimilars business is also growing, with revenues rising by 43% in the second quarter of 2021, driven by US demand for monoclonal antibodies Renflexis (infliximab-abda), for autoimmune diseases, and
Pharma giants Johnson &Johnson (J&J) and Pfizer have privately resolved a prolonged lawsuit relating to alleged anticompetitive practices revolving around the biosimilar market for infliximab. ... As a result – Pfizer alleged – this restricted use of
Meanwhile, as a rider to the licensing deal, Biogen has also taken on exclusive commercial rights to three other Samsung Bioepis TNF inhibitor biosimilars in China – Benepali (etanercept), Flixabi (infliximab) and
Remicade (infliximab) facing increasing competition from biosimilars.
More from news
Approximately 16 fully matching, plus 127 partially matching documents found.
Notably the biosimilar Renflexis (infliximab-abda) achieved a 70-80% price reduction to its reference product in both Norway and Denmark. ... The UK has been especially proactive with biosimilars. Three biologics there – infliximab, rituximab and
Specifically, Hospira was selling Inflectra, an infliximab biosimilar used to treat several chronic inflammatory diseases, notably the inflammation of Crohn’s disease, while Pfizer was in an advanced stage of developing ... its own biosimilar for
For example, since 2015, when the first monoclonal antibody biosimilar, infliximab, was launched in Europe we have seen a notable increase in the overall use of infliximab. ... Driving disparity. If we look across Europe at biosimilar penetration, even
We have many examples where small molecule and biosimilars have improved uptake such as the case of infliximab in Norway, which was supported by the government that sponsored clinical trials showing
RWE data presented at ECCO this year showed that switching to the biosimilar Remsima (infliximab) from the originator had no negative effect on safety and efficacy in 10 real-world studies.
More from intelligence
Approximately 0 fully matching, plus 12 partially matching documents found.
Positive experience of using infliximab biosimilars in gastro infusion clinics has had a big impact on the overall confidence of biosimilars. ... However, positive experience of switching in other therapy areas especially gastro patients receiving
So far, the introduction of biosimilar medicines seems to be progressing at a pace (uptake of the biosimilar infliximab was at a national average of 79.7% earlier this year), but
brands. Typically they are priced at a discount of 10-30%, and some infliximab biosimilars offer reductions of up to 60%. ... Last year an audit by the Royal College of Physicians showed that Remicade (infliximab) biosimilars were "safe, effective and
Despite heavy discounting of some biosimilars in certain markets such as France, the overall market share for these infliximab biosimilars is projected to remain relatively small.
More from PMHub
Approximately 0 fully matching, plus 4 partially matching documents found.
Onyx Health is a healthcare communications and PR agency based in the North East of England, but with a national...